ChiCTR2600128053 Ecnoglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines ChiCTR2600128053 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why ChiCTR2600128053 is a hot trial to watch
Obesity is being segmented by mechanism, treatment setting, geography and endpoint architecture. ChiCTR2600128053 is notable because it evaluates Ecnoglutide in a Phase 3 design sponsored by Wuhan Xiehe Hospital Tower. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | ChiCTR2600128053 |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ecnoglutide Injection in Participants with Obesity Combined with Knee Osteoarthritis (KOA) |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Ecnoglutide |
| Sponsor | Wuhan Xiehe Hospital Tower |
| Geography | China |
| Enrollment | 160 |
| Primary endpoint | Body weight |
| Endpoint time frame | After 52 weeks of treatment |
| Primary completion / readout proxy | 2028-12-31 |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Ecnoglutide in Obesity.
Allocation is not reported, masking is not reported, and the intervention model is Parallel Assignment. Planned enrollment of 160 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Body weight (After 52 weeks of treatment) — Use a calibrated scale within its valid calibration period. Whenever possible, the same scale shall be used for an individual participant. Ensure the scale is zeroed prior to weighing.Place the scale on a firm and flat surface. Do not use it on carpets, sloped or uneven surfaces.Instruct the participant to stand on the scale with one foot on each side. Ask the participant to remain still with arms at sides, then reco
- WOMAC Pain Subscale Score (After 52 weeks of treatment) — This study adopted the WOMAC 3.1 NRS version, which is an 11-point numeric rating scale ranging from "No symptoms/difficulty (score 0)" to "Extreme symptoms/difficulty (score 10)".Participants answered relevant questions based on their recollection of pain in the target knee over the preceding 24 hours. The total score was calculated in accordance with the guidelines specified in the WOMAC User Manual.
Readout outlook and evidence gap
The current protocol points to 2028-12-31 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: Ecnoglutide. The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: Wuhan Xiehe Hospital Tower. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
ChiCTR2600128053 provides a focused lens on Obesity development. Its value will be determined by whether Ecnoglutide can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
